HIV Diagnostics Market Size By Product [Antibody Tests (HIV-1 Screening, ELISA/EIA, Home Access Dried Blood Spot, Rapid Test, HIV-1 Confirmatory Steps, Western Blot, Indirect Immunoflorescent Antibody Assay (IIFA), Line Immunoassay , RadioImmuno Precipitation Assay (RIPA), HIV-2 & Group O Test, Blood Antibody, Dried Blood Spot), Viral Identification Assay (p24 Antigen, Qualitative PCR, Viral Culture), CD4, Viral Load, Early Infant Diagnosis], Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Japan, China, South Africa, Brazil), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023
Published Date: June 2016 | 126 Pages | Report ID: GMI491 Report Format: PDF
HIV Diagnostics Market size was USD 2.4 billion in 2015, and is forecast to grow at 9.5% CAGR up to 2023.
U.S. HIV Diagnostics Market Size, by Product, 2012 - 2023 (USD Million)
Growing HIV/AIDS prevalence, and rapid clinical developments in terms of point of care diagnostics will drive global HIV diagnostics market size throughout the forecast period.
HIV is found to be a common disease, especially in resource limited areas owing to low health awareness among the population, and successful implementation of antiretroviral treatment [ART] program, which allows people with HIV to live significantly longer, thus increasing percentage of HIV-infected people in their surroundings. The proportion of HIV infected population in South Africa has increased from 10.6% in 2008 to 12.2% from 2012 as per the estimates by Human Sciences Research Council's (HSRC) National HIV Prevalence, Incidence and Behavior Survey.
Rising prevalence of HIV has led to growing concern among the government driving them to incessantly invest in activities aimed at curbing disease burden costs of HIV/AIDS. Several such activities include encouraging population to take up regular early diagnosis tests. Multinational health care establishments such as UNITAID promote awareness and aid in finding novel techniques for diagnosis and eradication of HIV infection. Federal initiative by the government of Canada for treatment of HIV/AIDS at different levels of progression of this disease is expected to drive usage of HIV diagnostic tests.
Moreover, the need for more accuracy and cost-effective diagnostic tests has led to the introduction of novel technologies for diagnosis of HIV infection. Such novel technologies that are expected to be more accurate and feasible include CD4, drug resistance, viral load testing, and early infant diagnosis.
Growing point of care (PoC) diagnostics industry should positively impact the HIV diagnostics tests market. Various factors such as minimal equipment requirement, quick diagnosis, robustness, cost–effectiveness, and convenience to use should drive the HIV point of care diagnostics market. Technological advancement in biochemical engineering for design of these tests in order to allow simultaneous detection and quantification of multiple targets with utilization of resource limited settings are anticipated to fuel market growth for HIV diagnostics.
The key players in market are also focusing on collaborations for research activities to develop advanced point of care tests with high sensitivity, and specificity. There are many products in pipeline, expected to be commercialized in the coming year, impacting the industry growth positively. Some examples of these products are Chipcare CD4, MBIO CD4, and Visitect CD4 among others.
HIV Diagnostics Market, By Product
Antibody tests segment grabbed the largest overall HIV diagnostics market share, exceeding USD 1.5 billion by 2023. Widespread usage and, introduction of advanced PoC technologies designed to overcome the potential cell distinguishing drawbacks and provide quick and accurate results will drive segment growth.
CD4 and viral load testing are expected to grow at a relatively higher CAGR of 10.1% and 9.9% due to its rising market penetration as a result of development of point of care diagnostics for these tests which would enhance their marketability in resource limited settings.
HIV-1 screening tests were USD 455. 5 million and served to be major driving segment for antibody tests. This can be attributed to the rising prevalence of HIV disease coupled with high sensitivity, and quick turnaround time of these tests.
ELISA/ EIA was the predominant segment of HIV-1 screening tests market, while western blot test, and blood antibody test dominated the HIV-1 confirmatory tests, and HIV-2 & Group O diagnostics test respectively. Viral culture assay slated to reach USD 529 million by 2023, dominated the viral identification assay test market.
HIV Diagnostics Market, By Region
North America held a predominant chunk in the overall HIV diagnostics industry, valued at USD 946 million in 2015, rapid adoption of technologically advanced diagnostic solution service providers, and increasing demand for portable and point of care tests drives regional growth.
Moreover, a large pool of HIV patients and mandatory implementation of HIV screening tests should further contribute regional penetration. As per the statistics provided by WHO, 1.4 million people was infected with HIV/AIDS including adults as well as children by the end of 2011.
Asia Pacific should grow at 10.7% CAGR from 2016 to 2023, owing to improvement in access to healthcare facilities, along with increase in awareness levels amongst population in this region. Moreover, Asia Pacific has a large pool of HIV/AIDS patients which is expected to drive the market growth. The overall prevalence of HIV in most economies of this region is low, but as this region contributes 60% in total world’s population, low prevalence translates into large number of infected people.
Competitive Market Share
Global HIV diagnostics market share is competitive, garnered by the presence of number of large firms, and various small players. Market players are undergoing collaborations, and mutually beneficial agreements with smaller market entities to enter untapped markets. Roche Diagnostics, Siemens Healthcare, Abbott Healthcare, and Alere, Inc are major players in the market.
Other active players include Zyomyx, Inc. Qiagen, Inc., Sysmex Corporation, and Hologic, Inc. among others.
HIV Diagnostics Industry Background
The global HIV diagnostics market is highly influenced by point of care diagnostics industry. The decreasing laboratory standards and availability of lower number of technicians has generated the need for increased level of automation and self-contained systems that require minimal user maintenance. Efficient diagnosis unmet needs for HIV/AIDS treatment is expected to augment industry growth.
There is a trend of multiplex assays wherein several tests can be performed on the same sample at same time manufactured at much lower costs per test. Various clinical benefits, savings, and economic benefits can be achieved with more effective treatment, meeting the demands of both the healthcare providers, as well as patients.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security